Matinas Biopharm - MTNB STOCK NEWS

Welcome to our dedicated page for Matinas Biopharm news (Ticker: MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas Biopharm stock.

Matinas BioPharma Holdings, Inc. (NYSE: MTNB) is a clinical-stage biopharmaceutical company dedicated to advancing innovative anti-infective therapies for orphan indications. Utilizing proprietary lipid-crystal nano-particle cochleate technology, Matinas BioPharma aims to enhance the safety, tolerability, and oral bioavailability of existing drugs, thereby reducing their toxicity and improving patient outcomes.

The company's leading drug candidate, MAT2203, is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent. Currently in Phase 2 clinical trials, MAT2203 seeks to offer a less toxic and more effective oral treatment for severe fungal infections.

Another promising candidate is MAT2501, an orally-administered, encochleated formulation of amikacin. Amikacin is a broad-spectrum aminoglycoside antibiotic agent effective against acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections. MAT2501 is currently in Phase 1 clinical trials, following an open Investigational New Drug (IND) application.

Matinas BioPharma's innovative approach positions the company at the forefront of developing next-generation anti-infective therapies. The firm's pipeline also includes other drug candidates that aim to address unmet medical needs in infectious disease treatment. By leveraging its nano-encapsulation technology, Matinas BioPharma is committed to creating safer and more effective treatments for patients.

Latest News:

A photo accompanying this announcement is available
Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden, and improvement in lung infection.
Investor Contact: LHA Investor Relations, Jody Cain, Jcain@lhai.com, 310-691-7100

02/20/2024 07:30 AM

News

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Rhea-AI Summary

Matinas BioPharma announces alignment with the FDA on the design of a Phase 3 trial for MAT2203 in patients with invasive aspergillosis. The trial aims to provide a step-down treatment option for adults with limited or no treatment choices, focusing on all-cause mortality and treatment-related toxicities.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.91%

Tags

01/03/2024 07:00 AM

News

Matinas BioPharma to Present at Biotech Showcase 2024

Rhea-AI Summary

Matinas BioPharma (NYSE American: MTNB) announces CEO Jerome D. Jabbour will present a company overview at the Biotech Showcase 2024. The presentation will be available via webcast on the company's website. Institutional investors can schedule meetings with management.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.78%

Tags

12/27/2023 07:30 AM

News

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Rhea-AI Summary

Matinas BioPharma Holdings, a clinical-stage biopharmaceutical company (NYSE American: MTNB), reports successful oral delivery of LNC-formulated small single-strand oligonucleotides targeting key inflammatory cytokines TNFα and IL-17A in acute colitis and psoriasis models, showing significant reductions in serum TNFα levels and tissue IL-17A mRNA, with improvements in clinical disease markers.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

20.3%

Tags

12/21/2023 07:30 AM

News

Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

Rhea-AI Summary

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) receives positive feedback from FDA on Phase 3 study design for MAT2203, moving closer to full alignment with FDA. Partnership discussions ongoing. Meeting with FDA planned in early 2024 to finalize Phase 3 protocol.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.82%

Tags

11/08/2023 04:05 PM

News

Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update

Rhea-AI Summary

MTNB: Matinas BioPharma reports positive FDA feedback on MAT2203 Phase 3 program for invasive aspergillosis, acknowledging LPAD pathway potential. Oral LNC formulation of docetaxel shows comparable tumor reduction to IV-docetaxel in preclinical model.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-12.32%

Tags

11/07/2023 07:30 AM

News

Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Rhea-AI Summary

Matinas BioPharma Holdings, Inc. announces positive results from an in vivo animal study of an oral LNC formulation of docetaxel, showing reductions in tumor size comparable to IV docetaxel and no systemic toxicity.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

26.98%

Tags

11/01/2023 07:00 AM

News

Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023

Rhea-AI Summary

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) will report its third quarter 2023 financial results after market close on November 8, 2023. The company will host an investment community conference call and webcast at 4:30 p.m. Eastern time to discuss the results and provide a business update. Dial-in information is available for the call and the webcast will be archived on the company's website.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.57%

Tags

10/11/2023 07:30 AM

News

Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution

Rhea-AI Summary

Matinas BioPharma announces complete clinical resolution of patient's recurrent hemorrhagic cystitis with MAT2203

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

313.55%

Tags

09/28/2023 07:00 AM

News

Matinas BioPharma to Present at Two Investment Conferences in October 2023

Rhea-AI Summary

Matinas BioPharma to present at investment conferences on October 12 and October 19, 2023

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.52%

Tags

09/27/2023 07:00 AM

News

Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek

Rhea-AI Summary

Matinas BioPharma announces that MAT2203, its oral LNC formulation of amphotericin B, will be featured in a company pipeline presentation at IDWeek. The presentation will highlight clinical evidence supporting the ability of MAT2203 to improve outcomes for patients with fungal infections. MAT2203 reduces systemic toxicity and has the additional benefit of oral administration. The data presented at IDWeek support the development of an ideal antifungal agent.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.38%

Tags

FAQ

What is the current stock price of Matinas Biopharm (MTNB)?

The current stock price of Matinas Biopharm (MTNB) is $0.5798 as of February 28, 2025.

What is the market cap of Matinas Biopharm (MTNB)?

The market cap of Matinas Biopharm (MTNB) is approximately 2.9M.

What is Matinas BioPharma Holdings, Inc.?

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative anti-infective therapies for orphan indications.

What is MAT2203?

MAT2203 is an orally-administered, encochleated formulation of amphotericin B, a broad-spectrum fungicidal agent, currently in Phase 2 clinical trials.

What is MAT2501?

MAT2501 is an orally-administered, encochleated formulation of amikacin, an antibiotic agent for acute bacterial infections, currently in Phase 1 clinical trials.

What technology does Matinas BioPharma use?

Matinas BioPharma uses proprietary lipid-crystal nano-particle cochleate technology to enhance drug safety, tolerability, and oral bioavailability.

What are the benefits of MAT2203?

MAT2203 aims to offer a safer, less toxic, and more effective oral treatment for severe fungal infections.

What types of infections does MAT2501 target?

MAT2501 targets acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram-negative bacterial infections.

What is unique about Matinas BioPharma's approach?

Matinas BioPharma's approach is unique due to its use of lipid-crystal nano-particle cochleate technology, which improves the safety and effectiveness of existing drugs.

Who can I contact for investor relations inquiries?

For investor relations inquiries, contact Jody Cain at LHA Investor Relations via email at Jcain@lhai.com or by phone at 310-691-7100.

What is the status of MAT2203 clinical trials?

MAT2203 is currently in Phase 2 clinical trials.

What recent achievements has Matinas BioPharma reported?

Recent achievements include studies demonstrating prolonged survival and reduced fungal burden in a neutropenic mouse model.

Matinas Biopharm

NYSE:MTNB

MTNB Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

MTNB Stock Data

Market Cap 2.95M

Float 4.56M

Insiders Ownership 2.49%

Institutions Ownership 26.08%

Short Percent 0.65%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City BEDMINSTER